Biosimilar drugs for five important biological products by 2020
Biosimilar drugs for five important biological products by 2020 June 29, 2016 Source: Bio Valley June 24, 2016 / Bio Valley BIOON / -- The global leader in biosimilars - Swiss pharmaceutical giant Novartis's generics unit Sandoz recently revealed that by 2020 Biosimilars will be launched in five major oncology and immunization biologics, including Enbrel (Amgen, global sales of $9 billion in 2014), Humira (Aberdeen, global sales in 2014) $13 billion), Neulasta (Amgen, global sales of $5.8 billion in 2014), Remicade (Johnson Johnson, global sales of $9.3 billion in 2014), Rituxan/MabThera (Roche, global sales of $7.5 billion in 2014) The combined annual sales of these branded drugs are close to $44 billion. At present, Sandoz is advancing a radical regulatory submission strategy, and plans to submit 11 biosimilar drug regulatory applications within three years (2015-2017). Six of them have been completed so far, and three biosimilar drugs have been implemented. Listing. The company said that by 2020 there will be a total of eight biosimilar products on the market. Richard Francis, director and CEO of Sandoz, said that drug access is still the largest unmet medical need, both in developed and developing countries. In recent years, biological agents have revolutionized the clinical treatment of many disabling and even life-threatening diseases. However, there are still too many people who do not have access to the drugs they need. The company's high-quality biosimilars are clinically comparable to the original drug and, in some cases, offer up to a 75% discount, with the goal of significantly expanding access to high-quality, low-cost biosimilars worldwide. . Currently, the pharmaceutical industry is very optimistic about the prospects of biosimilar drugs. According to a report recently released by IMS, in Europe and the United States, the expanded access to biosimilar drugs will save the medical system by as much as $110 billion by 2020. This report highlights the market potential of biosimilars. However, the report also pointed out that the price factor alone is not enough to release the full potential of biosimilar drugs, and balanced and adequate education and training for medical personnel, patients and taxpayers is also a key factor. In the long run, it is important to ensure the sustainability of all stakeholders, including pharmaceutical manufacturers. Injection Solution,Compound Vitamin B Injection,Astragalus Polysaccharide Injection,Sulfamonomethoxine Sodium Injection Sichuan Aibang Weiye Biological Engineering Co., Ltd. , https://www.aibangpharm.com